Penumbra (PEN) Equity Income (2017 - 2018)
Penumbra (PEN) reported Equity Income of -$920000.0 for Q3 2018, down 68.81% year-over-year from -$2.9 million in Q3 2017, and up 25.2% on a QoQ basis from -$1.2 million in Q2 2018.
Penumbra (PEN) has 2 years of Equity Income data on file, last reported at -$920000.0 in Q3 2018.
- Quarterly Equity Income fell 68.81% year-over-year to -$920000.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was -$920000.0 (up 73.36% YoY) and the FY2018 annual result came in at -$3.1 million, down 116.85% from the prior year.
- Equity Income rose to -$920000.0 in Q3 2018 per PEN's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Equity Income topped out at -$158000.0 in Q2 2017 and bottomed at -$1.2 million in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -920,000.00 |
| Jun 30, 2018 | -1.23 Mn |
| Mar 31, 2018 | -951,000.00 |
| Dec 31, 2017 | -727,000.00 |
| Sep 30, 2017 | -545,000.00 |
| Jun 30, 2017 | -158,000.00 |